Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 26;11:2185. doi: 10.1038/s41598-020-80911-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of FDMC on colorectal tumour growth, metastasis, inflammation, and angiogenesis markers, β-catenin expression and induction of apoptosis in mice, as evidenced by comparisons with vehicle-treated controls (V = vehicle). (a) Luciferase bioluminescence image shows that treatment with FDMC (200 mg/kg, orally, twice a week) for 4 weeks decreased tumour growth in mice. (b) FDMC significantly decreased tumour volume 2 weeks after treatment (*p < 0.05) and more significantly (**p < 0.01) after 3 to 4 weeks of treatment. (c) FDMC significantly decreased tumour weight 4 weeks after treatment (*p < 0.01). (d) Luciferase bioluminescence image shows that FDMC decreased the numbers of liver metastasis nodules in mice. (e) FDMC significantly decreased liver metastases (luminescence units) mice (*p < 0.01). (f,g) Histology data of colorectal tumours show that FDMC significantly inhibited tumour cell proliferation (Ki-67) and tumour angiogenesis (CD31). (h) Western blot data depict the depletion of markers for inflammatory, angiogenesis, and metastasis (NF-kB, VEGF and MMP9) and induced apoptosis (C-PARP) in the tumour tissue of mice treated with FDMC compared with vehicle. Results are mean ± SEM (bars; n = 3–5).